PTTG1-mediated reprogramming of asparagine metabolism enhances DNA damage repair and leads to compromised antitumor immunity in prostate cancer.

IF 2.3 3区 医学 Q3 ONCOLOGY
Kuo Ma, Zeyu Li, Chunfeng Zhang, Guangye Han, Weihang Song, Lei Li
{"title":"PTTG1-mediated reprogramming of asparagine metabolism enhances DNA damage repair and leads to compromised antitumor immunity in prostate cancer.","authors":"Kuo Ma, Zeyu Li, Chunfeng Zhang, Guangye Han, Weihang Song, Lei Li","doi":"10.1016/j.urolonc.2025.09.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>CD8<sup>+</sup>T cell dysfunction is a key factor in immune escape of prostate cancer (PCa). While pituitary tumor-transforming gene 1 (PTTG1) exhibits oncogenic effects in multiple cancers, its role in PCa immunoregulation remains unclear.</p><p><strong>Methods: </strong>Bioinformatics analysis of TCGA data evaluated PTTG1 expression, prognosis, and CD8<sup>+</sup>T cell infiltration. qRT-PCR and western blot (WB) assessed PTTG1 levels in PCa cells. CD8<sup>+</sup>T cell cytotoxicity was measured via LDH release and ELISA (GZMB/TNF-α/IFN-γ). DNA damage was quantified by comet assay and γ-H2AX immunofluorescence. The metabolism of asparagine (Asn) was evaluated by detecting the content of Asn through a kit and the expression of asparagine synthase (ASNS) through WB. A mouse model of allograft tumor was constructed, and the mechanism was verified by immunohistochemistry (PTTG1, ASNS, γ-H2AX, KI67) and flow cytometry detection (proportion of CD8<sup>+</sup>T cells).</p><p><strong>Results: </strong>Bioinformatics analysis revealed that PTTG1 was highly expressed in PCa, positively correlated with the poor prognosis of patients, and negatively correlated with CD8<sup>+</sup>T cell infiltration. Cell experiments further demonstrated that PTTG1 inhibited the killing effect of CD8<sup>+</sup>T cells on PCa cells. In addition, in vitro and in vivo experiments showed that PTTG1 promoted DNA damage repair (DDR) of PCa by reprogramming Asn, and targeting PTTG1 enhanced the anti-tumor activity of CD8<sup>+</sup>T cells.</p><p><strong>Conclusion: </strong>PTTG1 promotes DDR by reprogramming Asn metabolism, thereby inhibiting the function of CD8<sup>+</sup>T cells. Targeting PTTG1 can reverse this process, providing a new strategy for PCa immunotherapy.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2025.09.005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: CD8+T cell dysfunction is a key factor in immune escape of prostate cancer (PCa). While pituitary tumor-transforming gene 1 (PTTG1) exhibits oncogenic effects in multiple cancers, its role in PCa immunoregulation remains unclear.

Methods: Bioinformatics analysis of TCGA data evaluated PTTG1 expression, prognosis, and CD8+T cell infiltration. qRT-PCR and western blot (WB) assessed PTTG1 levels in PCa cells. CD8+T cell cytotoxicity was measured via LDH release and ELISA (GZMB/TNF-α/IFN-γ). DNA damage was quantified by comet assay and γ-H2AX immunofluorescence. The metabolism of asparagine (Asn) was evaluated by detecting the content of Asn through a kit and the expression of asparagine synthase (ASNS) through WB. A mouse model of allograft tumor was constructed, and the mechanism was verified by immunohistochemistry (PTTG1, ASNS, γ-H2AX, KI67) and flow cytometry detection (proportion of CD8+T cells).

Results: Bioinformatics analysis revealed that PTTG1 was highly expressed in PCa, positively correlated with the poor prognosis of patients, and negatively correlated with CD8+T cell infiltration. Cell experiments further demonstrated that PTTG1 inhibited the killing effect of CD8+T cells on PCa cells. In addition, in vitro and in vivo experiments showed that PTTG1 promoted DNA damage repair (DDR) of PCa by reprogramming Asn, and targeting PTTG1 enhanced the anti-tumor activity of CD8+T cells.

Conclusion: PTTG1 promotes DDR by reprogramming Asn metabolism, thereby inhibiting the function of CD8+T cells. Targeting PTTG1 can reverse this process, providing a new strategy for PCa immunotherapy.

pttg1介导的天冬酰胺代谢重编程增强了DNA损伤修复,导致前列腺癌抗肿瘤免疫功能受损。
背景:CD8+T细胞功能障碍是前列腺癌(PCa)免疫逃逸的关键因素。虽然垂体肿瘤转化基因1 (PTTG1)在多种癌症中表现出致癌作用,但其在前列腺癌免疫调节中的作用尚不清楚。方法:生物信息学分析TCGA数据,评估PTTG1表达、预后和CD8+T细胞浸润情况。qRT-PCR和western blot (WB)检测PTTG1在PCa细胞中的表达。通过LDH释放和ELISA (GZMB/TNF-α/IFN-γ)检测CD8+T细胞毒性。采用彗星法和γ-H2AX免疫荧光法定量检测DNA损伤。通过试剂盒检测天冬酰胺(Asn)含量,WB检测天冬酰胺合成酶(ASNS)表达,评价天冬酰胺(Asn)代谢。建立小鼠同种异体移植瘤模型,通过免疫组化(PTTG1、ASNS、γ-H2AX、KI67)和流式细胞术检测(CD8+T细胞比例)验证其作用机制。结果:生物信息学分析显示PTTG1在PCa中高表达,与患者预后不良呈正相关,与CD8+T细胞浸润呈负相关。细胞实验进一步证实PTTG1抑制CD8+T细胞对PCa细胞的杀伤作用。此外,体外和体内实验表明,PTTG1通过重编程Asn促进PCa的DNA损伤修复(DDR),靶向PTTG1可增强CD8+T细胞的抗肿瘤活性。结论:PTTG1通过重编程Asn代谢来促进DDR,从而抑制CD8+T细胞的功能。靶向PTTG1可以逆转这一过程,为PCa免疫治疗提供了新的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
3.70%
发文量
297
审稿时长
7.6 weeks
期刊介绍: Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信